1. Home
  2. HUBB vs ILMN Comparison

HUBB vs ILMN Comparison

Compare HUBB & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hubbell Inc

HUBB

Hubbell Inc

HOLD

Current Price

$445.73

Market Cap

23.2B

Sector

Technology

ML Signal

HOLD

Logo Illumina Inc.

ILMN

Illumina Inc.

HOLD

Current Price

$134.65

Market Cap

18.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HUBB
ILMN
Founded
1888
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Medical Specialities
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.2B
18.9B
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
HUBB
ILMN
Price
$445.73
$134.65
Analyst Decision
Buy
Hold
Analyst Count
6
15
Target Price
$474.00
$114.93
AVG Volume (30 Days)
483.4K
1.6M
Earning Date
02-03-2026
10-30-2025
Dividend Yield
1.27%
N/A
EPS Growth
15.10
N/A
EPS
15.99
4.46
Revenue
$5,686,200,000.00
$4,288,000,000.00
Revenue This Year
$5.89
N/A
Revenue Next Year
$7.65
$2.08
P/E Ratio
$28.02
$30.24
Revenue Growth
0.82
N/A
52 Week Low
$299.43
$68.70
52 Week High
$484.26
$153.06

Technical Indicators

Market Signals
Indicator
HUBB
ILMN
Relative Strength Index (RSI) 53.89 68.81
Support Level $437.80 $126.44
Resistance Level $466.67 $137.09
Average True Range (ATR) 10.51 3.52
MACD 2.61 0.01
Stochastic Oscillator 54.17 81.58

Price Performance

Historical Comparison
HUBB
ILMN

About HUBB Hubbell Inc

Founded in 1888 by Harvey Hubbell, the eponymous company was the conduit through which the pull-chain lamp socket was originally sold. Hubbell has since grown into an electricity transmission and distribution behemoth, housing more than 75 brands that sell components found on power lines, electrical substations, and within commercial and industrial buildings. The company's primary operations are within the United States, where around 90% of revenue is derived.

About ILMN Illumina Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Share on Social Networks: